Clinical Trial: The Effect of Conbercept Injection Through Different Routes for Neovascular Glaucoma

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: The Effect of Conbercept Injection Through Different Routes for Neovascular Glaucoma

Brief Summary: The neovascular glaucoma (NVG) is a refractory type of secondary glaucoma and often lead to frustrated treatment and blindness. It has been confirmed high levels of vascular endothelial growth factor (VEGF) in NVG. Conbercept is an anti-VEGF agent，its role in regression of other neovascular disorders such as wet-type age-related macular degeneration and diabetic retinopathy has been described. Investigators aim to evaluate the efficacy and safety of intracameral and intravitreal injection of conbercept for the treatment of NVG.

Detailed Summary: The neovascular glaucoma (NVG) is a refractory type of secondary glaucoma and often lead to frustrated treatment and blindness. It has been confirmed high levels of vascular endothelial growth factor (VEGF) in NVG. Conbercept is an anti-VEGF agent，Its role in regression of other neovascular disorders such as wet-type age-related macular degeneration and diabetic retinopathy has been described. The intravitreal injection of anti-VEGF agent has shown its therapeutic potential for the early stage of NVG, but not for the late stage. Intracameral injection maybe used as an alternative way for administration. Investigators aim to evaluate the efficacy and safety of intracameral and intravitreal injection of conbercept for the treatment of NVG.
Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University

Current Primary Outcome: NVI/NVA [ Time Frame: 1 week and 1 month after operation ]

Changes in extent of iris or angle neovascularization


Original Primary Outcome: Same as current

Current Secondary Outcome:

  • IOP [ Time Frame: 1 week and 1 month after operation ]
    Changes in Intraocular pressure
  • BCVA [ Time Frame: 1 week and 1 month after operation ]
    Changes in best corrected visual acuity


Original Secondary Outcome: Same as current

Information By: Second Affiliated Hospital of Xi'an Jiaotong University

Dates:
Date Received: May 7, 2017
Date Started: April 1, 2017
Date Completion: December 31, 2017
Last Updated: May 14, 2017
Last Verified: May 2017